Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis
Year: 2025
Type: article
Study design: Observational Study
Abstract: Expression of CD2, CD25 and/or CD30 in extracutaneous mast cells (MC) is a minor diagnostic criterion for systemic mastocytosis (SM) in the classification of the World Health Organization and International Consensus Classification. So far, it remains unknown whether expression of these antigens on MC is of prognostic significance in SM. We performed a retrospective multi-center study of patients with SM using the data set of the registry of the European Competence Network on Mastocytosis, including 5034 patients with various MC disorders. The percentage of CD2-, CD25+ and/or CD30+ MC was considerably lower in patients with indolent SM compared to patients with advanced SM, including aggressive SM and MC leukemia. Whereas CD25 and CD30 expres-sion in MC could not be associated with prognosis, we found that lack of CD2 expression in MC is associated with a significantly reduced overall survival (OS) in patients with SM (p<0.0001). Lack of CD2 was also associated with the presence of extramedullary involvement affecting the spleen, liver, and/or lymph nodes (odds ratio 2.63 compared to SM with CD2+ MC). Together, lack of CD2 expression in MC is an important prognostic marker and indicator of reduced OS and extramedul-lary disease expansion in patients with SM.
Source: Leukemia
Authors: Axel Rüfer, Henning Nilius, Olivier Hermine, Marek Niedoszytko, Joanne N. G. Oude Elberink, Patrizia Bonadonna, Khalid Shoumariyeh, Theo Gulen, Karin Hartmann, Vito Sabato, Irena Angelova-Fischer, Daniel Baffoe, Deborah Christen, Anna Belloni Fortina, Christine Breynaert, Knut Brockow, Nikolas von Bubnoff, Horia Bumbea, Paul van Daele, Michael Doubek, Ingunn Dybedal, Chiara Elena, Christos Fokoloros, Aleksandra Górska, Marc Heizmann, Madlen Jentzsch, Saskia Klein, Johannes Lübke, Mattias Mattsson, André Mulder, Jens Panse, Tanja Daniela Schug, Mariarita Sciumè, Alex Stefan, Marlena Sztormowska, Judit Várkonyi, Friederike Wortmann, Akif Selim Yavuz, Martina Sperr, Jason Gotlib, Andreas Reiter, Massimo Triggiani, Wolfgang R. Sperr, Peter Valent
Institutions: University of Lucerne, Luzerner Kantonsspital, University Hospital of Bern, Inserm, Sorbonne Paris Cité, Institut des Maladies Génétiques Imagine, Gdańsk Medical University, University Medical Center Groningen, University of Groningen, Azienda Ospedaliera Universitaria Integrata Verona, University of Freiburg, German Cancer Research Center, University Medical Center Freiburg, Deutsches Konsortium für Translationale Krebsforschung, Karolinska University Hospital, Karolinska Institutet, University Hospital of Basel, University of Antwerp, Kepler Universitätsklinikum, Oslo University Hospital, Universitätsklinikum Aachen, RWTH Aachen University, University of Padua, Azienda Ospedale - Università Padova, Universitair Ziekenhuis Leuven, KU Leuven, Technical University of Munich, University Hospital Schleswig-Holstein, University of Lübeck, Carol Davila University of Medicine and Pharmacy, Bucharest Emergency University Hospital, Erasmus University Rotterdam, University Hospital Brno, Policlinico San Matteo Fondazione, University General Hospital Attikon, Kantonsspital Aarau, University Hospital Leipzig, Heidelberg University, University Medical Centre Mannheim, Uppsala University, Uppsala University Hospital, Medical University of Graz, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Semmelweis University, Istanbul University, Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, University of California, San Francisco, Stanford Cancer Institute, Stanford University, University of Salerno
Language: English
Topic: Mast cells and histamine
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W4406404895